As of March 2020, only one MERS vaccine (DNA-based) has completed Phase I clinical trials in humans and three more are underway; all vaccines were viral vectored, two adenoviral vectored (ChAdOx1-MERS, BVRS-GamVac) and one MVA vectored (MVA-MERS-S).
Hadi Machi2020, kulikuwa na chanjo moja ya MERS (inayotegemea DNA) iliyokamilisha majaribio ya awamu ya I ya kliniki kwa wanadamu, na zingine tatu zinaendelea, zote ambazo ni chanjo ya kuzuia virusi, virusi viwili ya DNA (ChAdOx1-MERS, BVRS-GamVac), na MVA-vectored (MVA-MERS-S).